Skip to main content
UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
24.12
+0.35 (1.47%)
At close: Apr 28, 2026, 4:00 PM EDT
24.29
+0.17 (0.70%)
Pre-market: Apr 29, 2026, 8:13 AM EDT

UroGen Pharma Revenue

In the year 2025, UroGen Pharma had annual revenue of $109.79M with 21.45% growth. UroGen Pharma had revenue of $37.84M in the quarter ending December 31, 2025, with 54.03% growth.

Revenue (ttm)
$109.79M
Revenue Growth
+21.45%
P/S Ratio
10.70
Revenue / Employee
$377,278
Employees
291
Market Cap
1.17B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025109.79M19.39M21.45%
Dec 31, 202490.40M7.69M9.29%
Dec 31, 202382.71M18.36M28.52%
Dec 31, 202264.36M16.32M33.96%
Dec 31, 202148.04M36.24M307.17%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Pharming Group 376.13M
AbCellera Biologics 75.13M
Septerna 45.95M
EyePoint 31.37M
uniQure 16.10M
Zenas BioPharma 10.00M
DBV Technologies 5.64M
Revenue Rankings

URGN News

More News